More Neurotech International Ltd. news
Neurotech International Ltd.ASX: NTI

Approval for Additional Phase I/II ASD Trial Extension

Feb 13, 2023 at 11:32 PM EST · Issued by Neurotech International Ltd.

Filed with ASX · Feb 13, 2023 at 11:32 PM EST

On 6ix: 6ix.com/news/approval-for-additional-phase-iii-asd-trial-extension

Neurotech International Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Neurotech International Ltd. on 6ix

Earlier from Neurotech International

  • HREC Approval for Phase I/II PANDAS/PANS Clinical TrialJan 26, 2023
  • NTI Granted FDA Pre-IND Meeting for NTI164 in ASDJan 19, 2023
  • Disclosure DocumentDec 22, 2022
  • Commencement of Phase II/III ASD Clinical TrialDec 19, 2022
  • NTI Receives HREC/TGA Approval for Phase II/III ASD TrialNov 16, 2022

Later from Neurotech International

  • First Patient Treated in Phase I/II PANDAS/PANS TrialFeb 16, 2023
  • Phase I/II ASD Clinical Trials Results at 52 WeeksMar 16, 2023
  • NTI to Launch Phase II Clinical Trial in Rett SyndromeMar 19, 2023
  • NTI Completes Recruitment in PANDAS/PANS Clinical TrialMay 2, 2023
  • NTI granted HREC Approval for PANDAS/PANS Trial ExtensionMay 29, 2023
All Neurotech International news releases↗

Follow Neurotech International into a list and get an email when it puts out news.

Follow Neurotech International
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer